OTX-TKI + Sham
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-proliferative Diabetic Retinopathy
Conditions
Non-proliferative Diabetic Retinopathy
Trial Timeline
Jan 15, 2023 → Dec 1, 2024
NCT ID
NCT05695417About OTX-TKI + Sham
OTX-TKI + Sham is a phase 1 stage product being developed by Ocular Therapeutix for Non-proliferative Diabetic Retinopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT05695417. Target conditions include Non-proliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05695417 | Phase 1 | UNKNOWN |
Competing Products
2 competing products in Non-proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | Ocular Therapeutix | Phase 3 | 72 |
| KSI-301 | Kodiak Sciences | Phase 3 | 72 |
Other Products from Ocular Therapeutix
Dextenza + Prednisolone AcetateApproved
80
Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved
80
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%Approved
80
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved
80